SynthesisBMC oral health2025
Survey methods contributing to the difference of dentin hypersensitivity prevalence among publications between 1998 and 2022: a research-on-research study.
Synthesis in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 38% silver diamine fluoride for dentine hypersensitivity treatment: anFrontiers in oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe prevalence of dentin hypersensitivity (DH) differed significantly among previous reports, which may confuse clinicians and public health practitioners. This study aimed to identify which survey methods contributed to the difference in reported DH prevalence.
methodsA systematic search was performed in Medline, Embase, ProQuest, CNKI, and ClinicalTrial.gov databases up to November 2022. Two authors extracted the basic characteristics and survey methods independently. A random-effect meta-analysis was performed to estimate the effects of survey methods on estimated DH prevalence. The Newcastle-Ottawa Scale (NOS) was employed to appraise the methodological quality of the studies included in the analysis.
resultsThirty-nine studies were included. The average estimate of DH prevalence was 32% (95% CIs: 27 - 37%). The statistical heterogeneity was very high among studies (I
conclusionThe included studies demonstrated substantial heterogeneity in survey methods. Conducting clinical examinations for all participants enhanced detection rates. The reliability of our pooled prevalence estimates was substantially compromised due to the studies' low methodological quality and high heterogeneity. It is recommended to propose the instructive detailed guideline to standardize the design and improve the quality of studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.